87 percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.
Data from this edition of Industry Statistics come from our report Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (4th Edition).
Originally published on Life Science Leader.
View Resource
